Biotest AG Vz Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 5/14/2025)
| Balance Sheet | Total Assets | 1,434,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 530,700,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -28,700,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 32,200,000.00 | – | – |
| Cashflow | Operating Cash Flow | 60,900,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.67 | Div. Yield | – |
| Income | Net Income | 26,400,000.00 | P/E | – |
| Income | Shares Outstanding | 39,571,500.00 | P/B | – |
| Income | Total Revenue | 726,200,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Biotest AG is a Germany-based international supplier of biological medications. It diversifies its activities into three business segments: Therapy segment, Plasma and Services segment, as well as Other segment. Its Therapy segment comprises the development and production of blood plasma-based immunoglobulin clotting factors and albumins, which are used in diseases of the immune system, hematological diseases, and intensive care medicine. It also includes the preclinical and clinical development of monoclonal antibodies, indications for which include rheumatoid arthritis and blood cancer. Furthermore, the Companys Plasma and Services segment includes the areas of plasma sales and toll manufacturing. Its Other segment, includes retail business and costs that cannot be allocated to the Therapy segment or the Plasma and Services segment.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biotest.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more